Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Dow
Harvard Business School
Mallinckrodt
Colorcon

Last Updated: July 3, 2022

CLINICAL TRIALS PROFILE FOR TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Tipiracil Hydrochloride; Trifluridine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01955837 ↗ Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia Completed Taiho Pharmaceutical Co., Ltd. Phase 3 2013-09-01 To compare the effects of TAS-102 with placebo in patients with metastatic colorectal cancer refractory or intolerable to standard chemotherapies.
NCT02654639 ↗ Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer Terminated Georgetown University Phase 2 2016-02-01 Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC
NCT03278106 ↗ TAS-102 in Treating Advanced Biliary Tract Cancers Active, not recruiting National Cancer Institute (NCI) Phase 2 2017-10-20 This phase II trial studies how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NCT03278106 ↗ TAS-102 in Treating Advanced Biliary Tract Cancers Active, not recruiting Mayo Clinic Phase 2 2017-10-20 This phase II trial studies how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NCT03297710 ↗ TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery Active, not recruiting National Cancer Institute (NCI) Phase 1 2017-12-11 This phase I trial studies the side effects and best dose of trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) when given together with radiation therapy in treating patients with rectal cancer that has come back, spread to other places in the body, or cannot be removed by surgery. Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving TAS-102 with radiation therapy may kill more tumor cells.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tipiracil Hydrochloride; Trifluridine

Condition Name

Condition Name for Tipiracil Hydrochloride; Trifluridine
Intervention Trials
Metastatic Colorectal Cancer 11
Stage IVC Colorectal Cancer AJCC v8 6
Stage IV Colorectal Cancer AJCC v8 6
Colorectal Cancer 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tipiracil Hydrochloride; Trifluridine
Intervention Trials
Colorectal Neoplasms 34
Adenocarcinoma 14
Colonic Neoplasms 8
Carcinoma 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tipiracil Hydrochloride; Trifluridine

Trials by Country

Trials by Country for Tipiracil Hydrochloride; Trifluridine
Location Trials
United States 110
Italy 24
Japan 18
Australia 11
Canada 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tipiracil Hydrochloride; Trifluridine
Location Trials
California 10
Arizona 8
Florida 8
Minnesota 8
Texas 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tipiracil Hydrochloride; Trifluridine

Clinical Trial Phase

Clinical Trial Phase for Tipiracil Hydrochloride; Trifluridine
Clinical Trial Phase Trials
Phase 3 10
Phase 2 27
Phase 1/Phase 2 4
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tipiracil Hydrochloride; Trifluridine
Clinical Trial Phase Trials
Recruiting 25
Not yet recruiting 10
Active, not recruiting 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tipiracil Hydrochloride; Trifluridine

Sponsor Name

Sponsor Name for Tipiracil Hydrochloride; Trifluridine
Sponsor Trials
National Cancer Institute (NCI) 14
Mayo Clinic 4
Academic and Community Cancer Research United 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tipiracil Hydrochloride; Trifluridine
Sponsor Trials
Other 48
Industry 28
NIH 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Dow
Harvard Business School
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.